OrthoPediatrics Corp. (NASDAQ:KIDS) Receives $26.44 Consensus PT from Analysts

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $26.4444.

KIDS has been the topic of several research analyst reports. Truist Financial set a $22.00 price target on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Needham & Company LLC upped their price objective on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. BTIG Research reiterated a “buy” rating and issued a $29.00 target price on shares of OrthoPediatrics in a research note on Monday, September 14th. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Finally, TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th.

Insiders Place Their Bets

In other news, major shareholder Squadron Capital Llc sold 302,369 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the sale, the insider directly owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. The trade was a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Jennifer N. Pritzker sold 302,369 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the transaction, the insider owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. The trade was a 4.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 2,100,000 shares of company stock worth $46,747,931. 32.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On OrthoPediatrics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Waverly Advisors LLC raised its stake in shares of OrthoPediatrics by 6.7% in the 2nd quarter. Waverly Advisors LLC now owns 12,366 shares of the company’s stock valued at $237,000 after purchasing an additional 775 shares during the period. Legal & General Group Plc bought a new position in shares of OrthoPediatrics during the second quarter worth about $34,000. Quantinno Capital Management LP acquired a new stake in OrthoPediatrics in the 1st quarter valued at approximately $160,000. FourThought Financial Partners LLC bought a new stake in OrthoPediatrics in the 4th quarter valued at approximately $197,000. Finally, R Squared Ltd acquired a new position in OrthoPediatrics during the 1st quarter worth approximately $212,000. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Trading Up 1.8%

OrthoPediatrics stock opened at $22.76 on Friday. The company’s fifty day simple moving average is $22.35 and its 200-day simple moving average is $19.28. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. OrthoPediatrics has a 12 month low of $14.42 and a 12 month high of $26.74. The stock has a market cap of $594.26 million, a P/E ratio of -13.55 and a beta of 0.99.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. The business had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. As a group, sell-side analysts forecast that OrthoPediatrics will post -1.14 EPS for the current fiscal year.

About OrthoPediatrics

OrthoPediatrics Corp. (NASDAQ: KIDS) develops, manufactures and sells orthopedic products designed specifically for children. The company focuses on addressing the distinct anatomical and clinical needs of pediatric patients, offering implants, instruments and related technologies for orthopedic surgery.

Its product portfolio includes solutions for pediatric trauma and deformity correction, scoliosis and spinal disorders, sports medicine, limb lengthening and reconstruction, and neuromuscular conditions.